![Dennis Mulroy](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dennis Mulroy
Finanzdirektor/CFO bei
ARCTURUS THERAPEUTICS HOLDINGS INC.
Vermögen: 929 813 $ am 30.06.2026
Profil
Dennis M.
Mulroy is Chief Financial Officer at Arcturus Therapeutics Holdings, Inc. since 2026.
Formerly, Chief Financial Officer at AnaptysBio, Inc. from 2020 to 2026.
CEO, Chief Financial & Accounting Officer at La Jolla Pharmaceutical Co. from 2015 to 2020.
Chief Financial Officer at Gene Biotherapeutics, Inc. from 2005 to 2015.
Chief Financial Officer, Treasurer & Director at Tissue Repair Co. from 2006 to 2013.
Chief Financial Officer at Aries Ventures, Inc. from 2005 to 2006.
Chief Financial Officer at Molecular Imaging Corp.
from 2004 to 2005.
Chief Financial Officer at SeraCare Life Sciences, Inc. from 2001 to 2003.
Chief Financial Officer at Bioceutix, Inc. in 2001.
Chief Financial Officer at Post-Hypothermia Corp.
Education includes an undergraduate degree from the University of San Diego, conferred in 1978.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ANAPTYSBIO, INC. 0.05% | 01.06.2026 | 13’775 ( 0.05% ) | 929 813 $ | 30.06.2026 |
Aktive Positionen von Dennis Mulroy
| Unternehmen | Position | Beginn |
|---|---|---|
| ARCTURUS THERAPEUTICS HOLDINGS INC. | Finanzdirektor/CFO | 01.05.2026 |
Ehemalige bekannte Positionen von Dennis Mulroy
| Unternehmen | Position | Ende |
|---|---|---|
| ANAPTYSBIO, INC. | Finanzdirektor/CFO | 20.04.2026 |
| LA JOLLA PHARMACEUTICAL COMPANY | Vorstandsvorsitzender | 31.05.2020 |
Taxus Cardium Pharmaceuticals Group, Inc.
 Taxus Cardium Pharmaceuticals Group, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops and commercializes angiogenic gene therapy products for cardiovascular disease | Finanzdirektor/CFO | 03.04.2015 |
Tissue Repair Co.
 Tissue Repair Co. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company that develops wound healing products for chronic wounds and aftercare | Finanzdirektor/CFO | 02.01.2013 |
Aries Ventures, Inc.
 Aries Ventures, Inc. Financial ConglomeratesFinance Financial investment vehicle | Finanzdirektor/CFO | 23.01.2006 |
Ausbildung von Dennis Mulroy
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
64
Beziehungen ersten Grades
11
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 11 |
|---|---|
La Jolla Pharmaceutical Co.
 La Jolla Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops and commercializes patients life-threatening conditions | Health Technology |
Aries Ventures, Inc.
Aries Ventures, Inc. Financial ConglomeratesFinance Financial investment vehicle | Finance |
Molecular Imaging Corp.
 Molecular Imaging Corp. Medical/Nursing ServicesHealth Services Provides molecular imaging services | Health Services |
SeraCare Life Sciences, Inc.
 SeraCare Life Sciences, Inc. Medical SpecialtiesHealth Technology Develops and manufactures biological based products to serve the global life sciences industry | Health Technology |
Tissue Repair Co.
Tissue Repair Co. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company that develops wound healing products for chronic wounds and aftercare | Health Technology |
AnaptysBio, Inc.
 AnaptysBio, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company | Health Technology |
University of San Diego
 University of San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Post-Hypothermia Corp.
 Post-Hypothermia Corp. Medical SpecialtiesHealth Technology Manufactures and markets temperature modulation therapy devices | Health Technology |
Taxus Cardium Pharmaceuticals Group, Inc.
Taxus Cardium Pharmaceuticals Group, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops and commercializes angiogenic gene therapy products for cardiovascular disease | Health Technology |
Bioceutix, Inc. | |
Arcturus Therapeutics Holdings, Inc.
 Arcturus Therapeutics Holdings, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
